Does Myo-Inositol Insulin Resistance Meta-Analysis work?

The current Migaku evidence database contains 2 reusable source documents for Myo-Inositol Insulin Resistance Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove. - Objectives This umbrella review aimed to synthesize and appraise the evidence regarding the efficacy of inositol for Polycystic Ovary Syndrome (PCOS) by integrating meta-analyses of randomized controlled trials(RCTs), thereby assessing the robustness of the existing body of evidence. [Duan M (2026); evidence level 2] - GRADE assessment of 85 evidence items revealed no high-quality evidence; 18.9% were moderate, 40% low, and 41.1% very low quality. [Duan M (2026); evidence level 2] - Pooled analyses demonstrated that inositol significantly improved multiple outcomes compared to placebo/FA: it reduced serum luteinizing hormone (LH: MD -3.43 IU/L, 95% CI [-4.29, -2.56], P P P P P P = 0.03; ovulation rate: RR 2.75, 95% CI [1.71, 4.41], P Conclusion Inositol improves core PCOS manifestations. [Duan M (2026); evidence level 2] - Methods We searched four databases from inception to August 2025 for relevant RCT meta-analyses. [Duan M (2026); evidence level 2] - Conclusions and outlook Myo-inositol has a more acceptable safety profile than metformin, which is known to be associated with gastrointestinal adverse effects and, in rare cases, lactic acidosis. [Russo M (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.